ABVX INVESTOR ALERT: Investigation Of Abivax S.A. Announced By Holzer & Holzer, LLC


Date:

(MENAFN- GlobeNewsWire - Nasdaq) ATLANTA, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Abivax S.A. (“Abivax” or the“Company”) (NASDAQ: ABVX) complied with federal securities laws. On November 18, 2026, Scorpion Capital published a report alleging, among other things, that obefazimod exhibits high lipophilicity,“violates one of the industry's most basic screens for oral drug viability” and further alleges that the drug's properties“resembles the signature of persistent organic pollutants (POPs) and certain agrochemicals.” On this news, the price of the Company's stock dropped.

If you purchased Abivax stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at ... or Joshua Karr, Esq. at ..., call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023 and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, , and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
...


MENAFN20112026004107003653ID1111997556


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search